

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM678723

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
TARVEDA THERAPEUTICS, INC.		09/30/2021	Corporation:
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	OXFORD FINANCE LLC		
<b>Street Address:</b>	115 South Union Street, Suite 300		
<b>City:</b>	Alexandria		
<b>State/Country:</b>	VIRGINIA		
<b>Postal Code:</b>	22314		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5519848	PENTARIN	
<b>Registration Number:</b>	5751586	TARVEDA THERAPEUTICS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6173106001		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	6173105234		
<b>Email:</b>	prezase@gtlaw.com		
<b>Correspondent Name:</b>	Eugenia A. Prezas		
<b>Address Line 1:</b>	Greenberg Traurig, LLP		
<b>Address Line 4:</b>	Boston, MASSACHUSETTS 02110		
<b>NAME OF SUBMITTER:</b>	Eugenia A. Prezas		
<b>SIGNATURE:</b>	/Eugenia A. Prezas/		
<b>DATE SIGNED:</b>	10/04/2021		
<b>Total Attachments: 12</b>			
source=OxfordFinance_TarvedalPSecurityAgreement#page1.tif			
source=OxfordFinance_TarvedalPSecurityAgreement#page2.tif			
source=OxfordFinance_TarvedalPSecurityAgreement#page3.tif			
source=OxfordFinance_TarvedalPSecurityAgreement#page4.tif			

CH \$65.00 5519848

source=OxfordFinance\_TarvedaIPSecurityAgreement#page5.tif  
source=OxfordFinance\_TarvedaIPSecurityAgreement#page6.tif  
source=OxfordFinance\_TarvedaIPSecurityAgreement#page7.tif  
source=OxfordFinance\_TarvedaIPSecurityAgreement#page8.tif  
source=OxfordFinance\_TarvedaIPSecurityAgreement#page9.tif  
source=OxfordFinance\_TarvedaIPSecurityAgreement#page10.tif  
source=OxfordFinance\_TarvedaIPSecurityAgreement#page11.tif  
source=OxfordFinance\_TarvedaIPSecurityAgreement#page12.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of September 30, 2021 by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“**Oxford**”), as collateral agent (in such capacity, “**Collateral Agent**”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “**Lender**” and collectively, the “**Lenders**”), and TARVEDA THERAPEUTICS, INC., a Delaware corporation (“**Grantor**”).

### RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the “**Loan Agreement**,” capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and mask works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

*[Balance of Page Intentionally Left Blank]*

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.


GRANTOR:

Address of Grantor:

134 Coolidge Avenue  
Watertown, Massachusetts 02472

Attn: Brian Roberts, Chief Financial Officer

TARVEDA THERAPEUTICS, INC.

By:   
Name: Brian Roberts  
Title: Chief Financial Officer

COLLATERAL AGENT:

Address of Collateral Agent:

115 South Union Street  
Suite 300  
Alexandria, VA 22314

OXFORD FINANCE LLC

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

134 Coolidge Avenue  
Watertown, Massachusetts 02472

Attn: Brian Roberts, Chief Financial Officer

TARVEDA THERAPEUTICS, INC.

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

Address of Collateral Agent:

115 South Union Street  
Suite 300  
Alexandria, VA 22314

COLLATERAL AGENT:

OXFORD FINANCE LLC

By: \_\_\_\_\_  
Name: Colette H. Featherly  
Title: Senior Vice President

EXHIBIT A

Copyrights

Description

Registration Number

Registration Date

None

**EXHIBIT B**

**Patents**

<b>Tarveda Ref.</b>	<b>*Status</b>	<b>Application No.</b>	<b>Filing Date /Pub Date/ Issue Date</b>	<b>Application Title</b>
2065.1000AU	Granted	2013369982 2013369982	12/30/13 03/02/17	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000CA	Granted	2896571 2896571 2896571	12/30/13 07/03/14 11/21/17	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000CN	Granted	2013800686804 104936622A 104936622	12/30/13 09/23/15 05/28/19	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000CNDIV	Published	2019103881935 1101799995	12/30/13 08/30/19	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000IL	Granted	238994 238994 238994	12/30/13 07/30/15 11/01/19	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000IN	Granted	4722/DELNP/2015 4722/DELNP/2015 A 347937	12/30/13 11/27/15 09/28/20	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000JP	Granted	2015550852 2016505609 6118914	12/30/13 02/25/16 03/31/17	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000KR	Published	10-2015-7017269 10-2015-0100706	12/30/13 09/02/15	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000MX	Granted	2015-008503 / 360098	12/30/13 10/22/18	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000MY	Granted	PI2015001403 MY-172519-A	12/30/13 11/28/19	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000PCT	Natl Phase	PCT/US2013/078361 WO2014/106208	12/30/13 07/03/14	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000SG	Granted	11201504235U 11201504235U	12/30/13 07/05/17	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000SGDIV	Published	10201705514W 10201705514W	07/04/17 08/30/17	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000USCON2	Published	16/722,913 20200121808	12/20/19 04/23/20	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1000USPRO	Completed	61/746,866	12/28/12	NANOPARTICULATE TARGETED DRUG DELIVERY
2065.1000ZA	Granted	201504109 201504109	12/30/13 10/30/19	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1003AU	Granted	2015284236 2015284236	12/22/16 06/21/18	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003AUDIV	Granted	2018204037 2018204037	06/30/15 07/09/20	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003BR	Published	BR212016030926 5 BR212016030926 5	06/30/15 05/29/18	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003CA	Granted	2953371 2953371 2953371	06/30/15 01/07/16 08/24/21	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003CN	Granted	2015800448364 106573077 106573077	06/30/15 04/19/17 07/30/19	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003CNDIV	Published	201910762952X 110478495	06/30/15 11/22/19	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003EP	Published	15815040.9 3160518	06/30/15 05/03/17	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003HK	Published	17109618.4 1235700A	09/21/17 03/16/18	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003ID	Granted	P00201700600 2017/13175 IDP000064533	06/30/15 12/08/17 11/14/19	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF

Tarveda Ref.	*Status	Application No.	Filing Date /Pub Date/ Issue Date	Application Title
2065.1003IL	Granted	249647 249647 249647	06/30/15 04/29/21 06/30/21	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003IN	Granted	201617043274 201617043274 350624	06/30/15 03/31/17 11/02/20	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003JP	Granted	2017500064 2017520585 6602834	06/30/15 07/27/17 10/18/19	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003JPDIV	Allowed	2019-185670 2020-063241	06/30/15 04/23/20	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003KR	Granted	10 2017 7002414 10-2062025 10-2062025	06/30/15 01/03/20 12/27/19	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003MO	Granted	J/3886 J/3886	10/17/19 11/25/19	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003MX	Allowed	MX/a/2017/000080	06/30/15	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003PCT	National Phase	PCT/US2015/038569 WO2016/004048	06/30/15 01/07/16	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003PH	Allowed	1-2017-500023 PH 12017500023 A1	06/30/15 05/15/2017	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003RU	Granted	2016151859 2016151859 2695220	06/30/15 08/06/18 07/22/19	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003SG	Granted	11201610880R SG 11201610880R A 11201610880R	06/30/15 01/27/17 11/11/20	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003USCON	Granted	15/382,487 2017/0095569 9,750,818	12/16/16 04/06/17 09/05/17	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF **TRACK ONE APPLICATION**
2065.1003USCON2	Granted	15/652,947 2018/0000959 10,624,967	07/18/17 01/04/18 04/21/20	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003USDIV	Granted	15/652,957 2017/0312245 10,322,191	07/18/17 11/02/17 06/18/19	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003USDIV2	Published	16/793,094 2020/0206356	02/18/20 07/02/20	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003USPRO	Completed	62/019,001	06/30/14	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1003USPRO2	Completed	62/077,487	11/10/14	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1003USPRO3	Completed	62/150,413	04/21/15	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1003ZA	Granted	2016/08432 2016/08432	12/07/16 07/31/19	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1027EP	Published	15815763.6 3164420	06/30/15 05/10/17	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1027PCT	Natl Phase	PCT/US2015/038562 WO2016/004043	06/30/15 01/07/16	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1027USPRO	Completed	62/102,261	01/12/15	TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1004USPRO	Completed	62/019,003	06/30/14	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1005USPRO	Completed	62/020,615	07/03/14	PARTICLES INCORPORATING DRUG CONJUGATES OF TARGETING SCAFFOLDS AND FORMULATIONS THEREOF
2065.1025USPRO	Completed	62/084,306	11/25/14	TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF
2065.1037CA	Published	2993429 2993429	07/29/16 02/09/17	COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES



Tarveda Ref.	*Status	Application No.	Filing Date /Pub Date/ Issue Date	Application Title
2065.1037EP	Published	16 833 628.7 3328377	07/29/16 06/06/18	COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES
2065.1037PCT	Nat'l Phase	PC T/US2016/044775 WO2017/023779	07/29/16 02/09/17	COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES
2065.1037USPRO	Completed	62/199,414	07/31/15	COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES
2065.1037USPRO2	Completed	62/332,772	05/06/16	COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES
2065.1040CA	Published	2993478 2993478	07/29/16 02/09/17	COMPOSITIONS AND METHODS FOR IMMUNOMODULATION
2065.1040PCT	Nat'l Phase	PC T/US2016/044705 WO2017/023749	07/29/16 02/09/17	COMPOSITIONS AND METHODS FOR IMMUNOMODULATION
2065.1040USPRO	Completed	62/199,422	07/31/15	COMPOSITIONS AND METHODS FOR IMMUNOMODULATION
2065.1040USPRO2	Completed	62/332,838	05/06/16	COMPOSITIONS AND METHODS FOR IMMUNOMODULATION
2065.1041AU	Granted	2016343817 2016343817 2016343817	10/28/16 05/10/17 09/09/21	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1041CA	Published	3001712 3001712	10/28/16 05/04/17	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1041CN	Published	2016800763876 108473538	10/28/16 08/31/18	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1041EP	Published	16860972.5 3368546	10/28/16 09/05/18	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1041JP	Published	2018-521977 2018-535212	10/28/16 11/29/18	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1041HK	Published	19101677.7 1259311A	01/30/19 11/29/19	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1041US371	Allowed	15/770,513 2018/0221499	4/24/18 8/09/18	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1041PCT	Nat'l Phase	PC T/US2016/059529 WO2017/075495	10/28/16 05/04/17	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1041USPRO	Completed	62/247,336	10/28/15	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1041USPRO2	Completed	62/304,856	03/07/16	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1044KR	Published	10-2018-7027442 10-2018-0112060	02/23/17 10/11/18	HSP90-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1044PCT	Nat'l Phase	PC T/US2017/019040 WO2017/147240	02/23/17 08/31/17	HSP90-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1044USCON	Published	16/711,577 2020/0113877	12/12/19 04/16/20	HSP90-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1044US371	Granted	16/079,387 2019/0054072 10,548,881	08/23/18 02/21/19 02/04/20	HSP90-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1044USPRO	Completed	62/298,917	02/23/16	HSP90-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1044USPRO2	Completed	62/351,716	06/17/16	HSP90-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1064AU	Published	2017376766 2017376766	12/14/17 06/06/19	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1064CA	Published	3045041 3045041	12/14/17 06/21/18	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1064CN	Published	2017800764055 110049783	12/14/17 07/23/19	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1064EP	Published	17880077.7 3554558	12/14/17 10/23/19	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1064HK	Published	62020006161.7 40016060A	12/14/17 09/04/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1064JP	Published	2019-531463 2020-503289	12/14/17 01/30/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF

Tarveda Ref.	*Status	Application No.	Filing Date /Pub Date/ Issue Date	Application Title
2065.1064US371	Allowed	16/469,768 2020/0085960	06/14/19 03/19/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1064PCT	Natl Phase	PCT/US2017/066361 WO2018/112176	12/14/17 06/21/18	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1064USPRO	Completed	62/434,282	12/14/16	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1064USPRO2	Completed	62/449,260	01/23/17	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1064USPRO3	Completed	62/487,726	04/20/17	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1065AU	Published	2017348313 2017348313	10/27/17 04/18/19	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065CA	Published	3039065 3039065	10/27/17 05/03/18	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065CN	Published	2017800670170 109890423	10/27/17 06/14/19	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065EP	Published	17864950.5 3 532 104	10/27/17 09/04/19	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065HK	Published	62020003076.0 40013491A	02/20/20 08/07/20	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065IL	Published	265770 265770	10/27/17 06/60/19	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065JP	Published	2019-522709 2019532091	10/27/17 11/07/19	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065KR	Published	10-2019-7012310 20190075938	10/27/17 07/01/19	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065MX	Published	MX/a/2019/004963 MX/a/2019/004963	10/27/17 10/07/19	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065US371	Allowed	16/345,306 2019/0262460	04/26/19 08/29/19	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065TW	Published	106137137 201828992	10/27/17 06/21/18	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065USPRO	Completed	62/414,481	10/28/16	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1065PCT	Natl Phase	PCT/US2017/058701 WO2018/081521	10/27/17 05/03/18	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1067AU	Published	2018289351 2018289351	06/19/18 01/02/20	TARGETED THERAPEUTICS
2065.1067CA	Published	3067457 3067457	06/19/18 12/27/18	TARGETED THERAPEUTICS
2065.1067CN	Published	2018800415256 110785165	06/19/18 02/11/20	TARGETED THERAPEUTICS
2065.1067EP	Published	18821114.8 3641740	06/19/18 04/29/20	TARGETED THERAPEUTICS
2065.1067HK-CN	Published	62020013157.6 62020013157.6	08/04/20 12/04/20	TARGETED THERAPEUTICS
2065.1067HK-EP	Published	62020015489.1 40025673A	08/31/20 12/24/20	TARGETED THERAPEUTICS
2065.1067IL	Published	270933 270933	06/19/18 01/30/20	TARGETED THERAPEUTICS
2065.1067JP	Published	2019-570031 2020-524153	06/19/18 08/13/20	TARGETED THERAPEUTICS
2065.1067KR	Published	10-2019-7037902 20200016876	06/19/18 02/17/20	TARGETED THERAPEUTICS
2065.1067US371	Published	16/625,358 2020/0230126	12/20/19 07/23/20	TARGETED THERAPEUTICS
2065.1067USPRO	Completed	62/522,316	06/20/17	TARGETED THERAPEUTICS
2065.1067USPRO2	Completed	62/642,154	03/13/2018	TARGETED THERAPEUTICS
2065.1067PCT	National Phase	PCT/US2018/038174 WO2018/236793	06/19/18 12/27/18	TARGETED THERAPEUTICS

Tarveda Ref.	*Status	Application No.	Filing Date /Pub Date/ Issue Date	Application Title
2065.1070CA	Published	3100216 3100216	05/31/19 12/05/19	COMBINATION THERAPY
2065.1070CN	Published	2019800359157 112292126	05/31/19 01/29/21	COMBINATION THERAPY
2065.1070EP	Published	19810224.6 3801506	05/31/19 04/14/21	COMBINATION THERAPY
2065.1070HK	Published	62021033553.0 40044041	05/31/19 09/24/21	COMBINATION THERAPY
2065.1070TW	Published	108118962 202015675	05/31/19 05/01/20	COMBINATION THERAPY
2065.1070PCT	Natl Phase	PCT/US2019/034894 WO2019232366	05/31/19 12/05/19	COMBINATION THERAPY
2065.1070US371	Published	15/734,110 US20210186978	12/01/20 06/24/21	COMBINATION THERAPY
2065.1070USPRO	Completed	62/679,216	06/01/18	COMBINATION THERAPY
2065.1070USPRO2	Completed	62/788,326	01/04/19	COMBINATION THERAPY
2065.1070USPRO3	Completed	62/827,232	04/01/2019	COMBINATION THERAPY
2065.1074AU	Published	2018289354 2018289354	06/19/18 01/02/20	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1074CA	Published	3067454 3067454	06/19/18 12/27/2018	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1074CN	Published	2018800414696 110769857	06/19/18 02/07/20	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1074EP	Published	18820945.6 3641767	06/19/18 04/29/20	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1074HK-CN	Published	62020013153.5 40023858A	08/04/20 12/04/20	TARGETED THERAPEUTICS
2065.1074HK-EP	Published	62020015486.7 40025670	08/31/20 12/24/20	TARGETED THERAPEUTICS
2065.1074IL	Published	270934 270934	06/19/18 01/30/20	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1074JP	Published	2019-570040 2020-524677	06/19/18 08/20/20	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1074KR	Published	10-2019-7037911 20200016877	06/19/18 02/17/20	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1074US371	Published	16/625,362 2020/0230247	12/20/19 07/23/20	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1074USPRO	Completed	62/522,323	06/20/17	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1074USPRO2	Completed	62/679,224	06/01/18	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1074PCT	National Phase	PCT/US2018/038177 WO2018/236796	06/19/18 12/27/18	COMBINATION THERAPIES COMPRISING TARGETED CONSTRUCTS
2065.1076EP	Published	18820449.9 3641766	06/19/18 04/29/20	HSP90 TARGETED CONJUGATES AND PARTICLE FORMULATIONS THEREOF
2065.1076HK	Published	62020018948.3 40029497A	06/19/18 02/19/21	HSP90 TARGETED CONJUGATES AND PARTICLE FORMULATIONS THEREOF
2065.1076US371	Published	16/625,368 2020/0237746	12/20/19 07/30/20	HSP90 TARGETED CONJUGATES AND PARTICLE FORMULATIONS THEREOF
2065.1076USPRO	Completed	62/522,333	06/20/17	HSP90 TARGETED CONJUGATES AND PARTICLE FORMULATIONS THEREOF
2065.1076PCT	Nat'l Phase	PCT/US2018/038178 WO2018/236797	06/19/18 12/27/18	HSP90 TARGETED CONJUGATES AND PARTICLE FORMULATIONS THEREOF
2065.1080CA	Published	3078776 3078776	10/26/18 05/02/19	SSTR-TARGETED CONJUGATES AND FORMULATIONS THEREOF
2065.1080CN	Published	201880069470X 111479572A	10/26/18 07/31/20	SSTR-TARGETED CONJUGATES AND FORMULATIONS THEREOF
2065.1080EP	Published	18870791.3 3700533	10/26/18 09/02/20	SSTR-TARGETED CONJUGATES AND FORMULATIONS THEREOF
2065.1080JP	Published	2020-523379 2021-501154	10/26/18 01/14/21	SSTR-TARGETED CONJUGATES AND FORMULATIONS THEREOF

Tarveda Ref.	*Status	Application No.	Filing Date /Pub Date/ Issue Date	Application Title
2065.1080PCT	Nat'l Phase	PCT/US2018/057673 WO2019084377	10/26/18 05/02/19	SSSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1080US371	Published	16/759,438 2020-0281934	04/27/20 09/10/20	SSSTR-TARGETED CONJUGATES AND FORMULATIONS THEREOF
2065.1080USPRO	Completed	62/577,897	10/27/17	SSSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1080USPRO2	Completed	62/679,230	06/01/18	SSSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1082AU	Published	2018386218 2018386218	12/14/18 07/02/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082CA	Published	3085759 3085759	12/14/18 06/02/19	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082CN	Published	2018800894246 CN111971070A	12/14/18 11/20/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082EP	Published	18887279.0 3723811	12/14/18 10/21/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082HK	Published	62021027790.6 40038485	12/14/18 07/25/21	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082IL	Published	275208 275208	12/14/18 11/20/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082IN	Published	202017023633 202017023633	12/14/18 09/11/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082JP	Published	2020-532665 2021-506797	12/14/18 02/22/21	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082TW	Published	107145198 201936179	12/14/18 09/16/19	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082US371	Published	16/772,290 2021/0000966	06/12/20 01/07/21	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082PCT	Nat'l Phase	PCT/US2018/065657 WO2019/118830	12/14/18 06/20/19	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082USPRO	Completed	62/598,755	12/14/17	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082USPRO2	Completed	62/684,666	06/13/18	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082USPRO3	Completed	62/731,538	09/14/18	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082USPRO4	Completed	62/735,306	09/24/18	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1082USPRO5	Completed	62/757,955	11/09/18	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083CA	Published	3094719 3094719	04/03/19 10/10/19	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083CN	Published	201980022071.2 112074288	04/13/19 12/11/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083EP	Published	19782165.5 3773670	04/03/19 02/17/21	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083HK	Published	62021033407.9 40044285A	04/03/19 09/30/21	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083JP	Published	2020-554483 2021-521106	04/03/19 08/26/21	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083KR	Published	10-2020-702528 10-2020-0140271	04/03/19 12/15/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083TW	Published	108111939 2020-05667	04/03/19 02/01/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083PCT	Nat'l Phase	PCT/US2019/025524 WO2019/195384	04/03/19 10/10/19	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083US371	Published	17/045,320 US2021-0145971A1	10/05/20 05/20/21	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083USPRO	Completed	62/653,106	04/05/18	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF

Tarveda Ref.	*Status	Application No.	Filing Date /Pub Date/ Issue Date	Application Title
2065.1083USPRO2	Completed	62/731/543	09/14/18	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1083USPRO3	Completed	62/787,799	01/03/19	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1084CA	Published	3094721 3094721	04/03/19 10/10/19	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1084CN	Published	2019800230536 112040927	04/03/19 12/04/20	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1084EP	Published	19781700.0 3773488	04/03/19 02/17/21	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1084HK-CN	Published	62021031305.7 40043145	04/03/19 9/10/21	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1084HK-EP	Published	62021033405.3 40044283A	04/03/19 09/30/21	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1084JP	Published	2020-554490 2021-521107	04/03/19 08/26/21	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1084KR	Published	10-2020-7028525 10-2020-0141446	04/03/19 12/18/20	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1084TW	Published	108111940 2020-11940	04/03/19 04/01/20	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1084PCT	Nat'l Phase	PCT/US2019/025526 WO2019/195386	04/03/19 10/10/19	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1084US371	Published	17/045,325 US20210169871	10/05/20 06/10/21	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1084USPRO	Completed	62/653,118	04/05/18	PHARMACEUTICAL COMPOSITIONS WITH REDUCED TERT-BUTANOL LEVELS
2065.1086EP	Published	19859058.0 3849546	09/13/19 07/21/21	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1086USPRO	Completed	62/731,545	09/14/18	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1086PCT	Nat'l Phase	PCT/US2019/050916 WO2020056205	09/13/19 03/19/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1087PCT	Published	PCT/US2020/039260 WO2020263906	06/24/20 12/30/20	SSTR-TARGETED CONJUGATES AND FORMULATIONS THEREOF
2065.1087USPRO	Completed	62/866,134	06/25/19	SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
2065.1088TW	Published	109111249 202102268	04/01/20 01/16/21	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1088PCT	Published	PCT/US2020/026137 WO 2020/205948	04/01/20 10/08/20	HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF
2065.1088USPRO	Completed	62/828,645	04/03/19	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1088USPRO2	Completed	62986245	03/06/20	HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF
2065.1089TW	Published	109121478 202116318	06/24/20 05/01/21	HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF
2065.1089PCT	Published	PCT/US2020/039261 WO 2020/263907	06/24/20 12/30/20	HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF
2065.1089USPRO	Completed	62/866,140	06/25/19	HSP90 TARGETED CONJUGATES AND PARTICLE FORMULATIONS THEREOF
2065.1089USPRO2	Completed	63/035,048	06/05/20	HSP90-BINDING CONJUGATES AND COMBINATION THERAPIES THEREOF
2065.1091USPRO	Completed	62/899,777	09/13/19	TARGETED THERAPEUTICS

EXHIBIT C

Trademarks

Tarveda Ref.	Status	Application No.	Filing Date/ Issue Date	Trademark
2065.2000MP	Published	1252217	11/18/14	PENTARIN
2065.2000TM	Granted	86457303 86457303 5519848	11/18/14 04/23/15 07/17/18	
2065.2000TM.EP	Granted	1252217 1252217	04/22/15 04/20/16	
2065.2002TM	Granted	86874198 86874198 5751586	01/13/16 07/26/16 05/14/19	TARVEDA THERAPEUTICS
2065.2002TM.EP	Granted	15368319 15368319 15613995	07/06/16 10/11/16 09/27/18	